Skip to main content
ABCL logo

ABCL · AbCellera Biologics Inc.

Track ABCL — free
$11.38 +0.41 (+3.74%) At close · Aug 14
Market Cap
$3.49B
Shares
306.61M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Carl L.G. Hansen $6,293,085
Andrew Booth $3,382,244
Tryn Stimart $2,343,388
Véronique Lecault $2,315,758
Fiscal 2024
Executive Total
Carl L.G. Hansen $8,245,492
Andrew Booth $3,428,578
Véronique Lecault $3,424,564
Tryn Stimart $2,890,567
Fiscal 2023
Executive Total
Carl L.G. Hansen $714,939
Andrew Booth $674,555
Tryn Stimart $667,690
Véronique Lecault $650,587
Fiscal 2022
Executive Total
Carl L.G. Hansen $8,797,689
Neil Aubuchon $5,566,290
Andrew Booth $4,887,682
Véronique Lecault $4,688,188
Tryn Stimart $3,676,733
Fiscal 2021
Executive Total
Carl L.G. Hansen $9,116,252
Véronique Lecault $4,313,387
Andrew Booth $4,313,387
Tryn Stimart $3,063,678
Fiscal 2020
Executive Total
Carl L.G. Hansen $16,962,608
Véronique Lecault $5,950,539
Tryn Stimart $4,434,343
Fiscal 2019
Executive Total
Tryn Stimart $651,870
Carl L.G. Hansen $249,898

Executive changes

Person Change Filed
Lynn Seely, M.D. Appointed 2026-07-06
Victor Sandor Appointed 2026-06-05
Andrew Lo, Ph.D. Resigned 2025-11-12
Stephen Quake, D.Phil. Appointed 2025-11-12
Peter Thiel Retired 2024-02-23
Neil Berkley Terminated 2022-07-19
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 145 filings 143 filers Visit website Investor relations